<!DOCTYPE html>
<html lang="fa">
 <meta content="text/html;charset=utf-8" http-equiv="content-type"/>
 <head>
  <title>
   Lipid management in patients with nondialysis chronic kidney disease
  </title>
  <link href="d/css/1.css" rel="stylesheet"/>
 </head>
 <body>
  <!-- Start Main Menu Area -->
  <br/>
  <br/>
  <br/>
  <br/>
  <div class="container">
   <div class="row">
   </div>
  </div>
  <section class="teacher-area ptb-10">
   <div class="container">
   </div>
   <section class="course-details-area ptb-60">
    <div class="container">
     <div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
      <h1 style="text-align:center">
       Lipid management in patients with nondialysis chronic kidney disease
      </h1>
      <div class="utdArticleSection utdStyle" id="topicContent">
       <div id="topicTitle">
        Lipid management in patients with nondialysis chronic kidney disease
       </div>
       <div class="authorSectionElem">
        <div class="authorsElementsLeft">
         <dl id="topicContributors">
          <dt>
           <span>
           </span>
           Authors:
          </dt>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Alfred K Cheung, MD
           </a>
          </dd>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Florian Kronenberg, MD
           </a>
          </dd>
          <dt>
           <span>
           </span>
           Section Editors:
          </dt>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Gary C Curhan, MD, ScD
           </a>
          </dd>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Robert S Rosenson, MD
           </a>
          </dd>
          <dt>
           <span>
           </span>
           Deputy Editor:
          </dt>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            John P Forman, MD, MSc
           </a>
          </dd>
         </dl>
        </div>
        <div class="authorsElementsRight">
         <div id="literatureReviewDate">
          <div class="litReviewSingleLine">
           <bdi>
            <span class="emphasis">
             Literature review current through:
            </span>
            Jan 2024.
           </bdi>
          </div>
          <div class="litReviewSingleLine">
           <bdi>
            <span class="emphasis">
             This topic last updated:
            </span>
            Jan 31, 2024.
           </bdi>
          </div>
         </div>
        </div>
       </div>
       <div id="topicWhatsNewContainer">
       </div>
       <div id="topicText">
        <p class="headingAnchor" id="H1">
         <span class="h1">
          INTRODUCTION
         </span>
         <span class="headingEndMark">
          —
         </span>
         Lipoprotein abnormalities are common in patients with all stages of chronic kidney disease (CKD) [
         <a href="#rid1">
          1-9
         </a>
         ]. Hypertriglyceridemia is the primary lipid abnormality among patients with CKD, although abnormalities in cholesterol and apolipoproteins also occur [
         <a href="#rid10">
          10-12
         </a>
         ].
        </p>
        <p>
         This topic reviews the pathogenesis, epidemiology, and treatment of lipid and lipoprotein abnormalities in patients with nondialysis CKD. The pathogenesis and significance of lipid abnormalities in nephrotic syndrome and following kidney transplantation, the association between CKD and coronary heart disease (CHD), and the management of lipids in patients with CKD who require dialysis are discussed separately:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         (See
         <a class="medical medical_review" href="/z/d/html/3114.html" rel="external">
          "Lipid abnormalities in nephrotic syndrome"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         (See
         <a class="medical medical_review" href="/z/d/html/7303.html" rel="external">
          "Lipid abnormalities after kidney transplantation"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         (See
         <a class="medical medical_review" href="/z/d/html/7190.html" rel="external">
          "Chronic kidney disease and coronary heart disease"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         (See
         <a class="medical medical_review" href="/z/d/html/1962.html" rel="external">
          "Secondary prevention of cardiovascular disease in end-stage kidney disease (dialysis)", section on 'Lipid modification'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H3">
         <span class="h1">
          COMMON LIPID ABNORMALITIES
         </span>
         <span class="headingEndMark">
          —
         </span>
         As in patients without CKD, plasma lipoprotein abnormalities may involve triglycerides, cholesterol, high-density lipoprotein (HDL), and lipoprotein(a) (Lp(a)).
        </p>
        <p class="headingAnchor" id="H2631352014">
         <span class="h2">
          Triglycerides
         </span>
         <span class="headingEndMark">
          —
         </span>
         Hypertriglyceridemia is the primary lipid abnormality among patients with CKD. Approximately 40 to 50 percent of patients with CKD have fasting triglyceride levels &gt;200 mg/dL (2.26 mmol/L). In the absence of other comorbid conditions, hypertriglyceridemia is seldom profound; the plasma levels are usually below 500 mg/dL.
        </p>
        <p>
         High serum triglyceride concentrations and a high triglyceride/HDL cholesterol (HDL-C) ratio are risk markers of CKD [
         <a href="#rid13">
          13,14
         </a>
         ] and are associated with decline in eGFR and incidence of new-onset CKD [
         <a href="#rid15">
          15-18
         </a>
         ]. However, in a Mendelian randomization study, genetic variants associated with higher, life-long triglyceride concentrations were not associated with kidney disease [
         <a href="#rid19">
          19
         </a>
         ], suggesting that the relationship between serum triglycerides and kidney function decline is not causal. Higher triglycerides and a high triglyceride/HDL-C are also associated with atherosclerotic cardiovascular disease [
         <a href="#rid20">
          20,21
         </a>
         ] and all-cause mortality [
         <a href="#rid22">
          22,23
         </a>
         ], although not all studies support these observations [
         <a href="#rid24">
          24
         </a>
         ].
        </p>
        <p>
         Hypertriglyceridemia among patients with CKD is caused by an increased production rate and by a lower catabolic rate. Impaired carbohydrate tolerance and enhanced hepatic very-low-density lipoprotein (VLDL) synthesis might contribute to the increased production of triglyceride-rich lipoproteins [
         <a href="#rid2">
          2
         </a>
         ]. The reduced catabolic rate is likely caused by a decreased activity of the two enzymes lipoprotein lipase and hepatic triglyceride lipase, which cleave triglycerides into free fatty acids for energy production or storage [
         <a href="#rid3">
          3,4,25
         </a>
         ]. This impaired clearance results from alterations in the composition of circulating lipoproteins, which become enriched with apolipoprotein C-III, an inhibitor of lipoprotein lipase. This increases the ratio of the inhibitory apolipoprotein C-III to the activating apolipoprotein C-II, resulting in a net decrease plasma lipase activity, hence lower clearance rate of triglyceride-rich lipoproteins and accumulation of lipoprotein remnants in the plasma [
         <a href="#rid3">
          3,4,25,26
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/4565.html" rel="external">
          "Lipoprotein classification, metabolism, and role in atherosclerosis", section on 'Apolipoproteins'
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/132419.html" rel="external">
          "Hypertriglyceridemia in adults: Approach to evaluation", section on 'Atherosclerotic cardiovascular disease'
         </a>
         .)
        </p>
        <p>
         Other potential contributors to decreased triglyceride clearance in CKD include secondary hyperparathyroidism causing a decreased synthesis of lipoprotein lipase [
         <a href="#rid27">
          27-29
         </a>
         ] and the retention of other circulating inhibitors of lipoprotein lipase, such as pre-beta-HDL [
         <a href="#rid30">
          30
         </a>
         ]. Pre-beta-HDL is the HDL moiety that interacts with the ABCA1 transporter, which is critical for macrophage cholesterol efflux.
        </p>
        <p class="headingAnchor" id="H153500441">
         <span class="h2">
          Total and LDL cholesterol
         </span>
         <span class="headingEndMark">
          —
         </span>
         Approximately 20 to 30 percent of patients with CKD have total plasma cholesterol levels &gt;240 mg/dL (6.2 mmol/L) [
         <a href="#rid1">
          1-7
         </a>
         ]. It should be emphasized that various CKD subpopulations have markedly different plasma cholesterol concentrations, with very high concentrations in patients with nephrotic syndrome or patients treated by maintenance peritoneal dialysis, in contrast to the normal or low concentrations in patients on maintenance hemodialysis [
         <a href="#rid10">
          10
         </a>
         ].
        </p>
        <p>
         The clinical significance of elevated serum cholesterol concentrations among patients with CKD is not clear and appears to be somewhat different from patients without CKD. In patients without CKD, a higher serum total cholesterol level is progressively associated with an increased risk of coronary disease and cardiovascular death. Among patients with CKD, however, the association between low-density lipoprotein cholesterol (LDL-C) and coronary risk tends to diminish as the estimated glomerular filtration rate (eGFR) decreases [
         <a href="#rid31">
          31
         </a>
         ], and some studies have found no association between lipid levels and mortality among patients with CKD [
         <a href="#rid24">
          24,32,33
         </a>
         ]. There are studies suggesting that the association between serum total cholesterol concentration and cardiovascular disease is modified by the presence of inflammation and malnutrition, conditions that become more common with decreasing kidney function [
         <a href="#rid34">
          34,35
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/1506.html" rel="external">
          "Overview of established risk factors for cardiovascular disease", section on 'Lipids and lipoproteins'
         </a>
         .)
        </p>
        <p>
         An increased LDL-C/HDL-C ratio is commonly observed [
         <a href="#rid36">
          36
         </a>
         ]. The increased ratio is due to both a modest decrease in HDL-C [
         <a href="#rid37">
          37
         </a>
         ] and increased LDL-C [
         <a href="#rid36">
          36
         </a>
         ]. Approximately 10 to 45 percent of patients with CKD have LDL-C levels &gt;130 mg/dL (3.4 mmol/L) [
         <a href="#rid1">
          1-7
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H1362549701">
         <span class="h2">
          HDL cholesterol
         </span>
         <span class="headingEndMark">
          —
         </span>
         Although a low plasma HDL-C concentration is a well-established predictor of cardiovascular events in the general population, interventional trials that examine strategies to raise HDL-C concentrations failed to demonstrate the expected positive effect on clinical outcomes. The association between HDL-C concentration and cardiovascular outcomes in the general population, in fact, appears to be U-shaped [
         <a href="#rid38">
          38
         </a>
         ]; a similar U-shaped relationship exists between HDL-C concentration and the risk of infections [
         <a href="#rid39">
          39
         </a>
         ]. These U-shaped relationships might be one of the reasons that explain the lack of clinical benefits with pharmacologic lowering of plasma HDL-C. (See
         <a class="medical medical_review" href="/z/d/html/4560.html" rel="external">
          "HDL cholesterol: Clinical aspects of abnormal values"
         </a>
         .)
        </p>
        <p>
         Consistent with the aforementioned studies in the general population, a large study of more than 33,000 patients on hemodialysis revealed a U-shaped association with an increased risk for total and cardiovascular mortality in patients with plasma HDL-C concentrations below 30 mg/dL and above 60 mg/dL [
         <a href="#rid40">
          40
         </a>
         ]. A second study of 38,377 patients with eGFR 15 to 59 mL/min/1.73 m² found a U-shaped relationship with mortality in females, with a nadir at HDL-C of 50 mg/dL, but not in males [
         <a href="#rid41">
          41
         </a>
         ].
        </p>
        <p>
         Individuals with HDL-C concentrations &lt;30 mg/dL had a 10 to 20 percent higher risk for incident CKD and/or progression of CKD in one study compared with individuals whose HDL-C concentration was ≥40 mg/dL [
         <a href="#rid42">
          42
         </a>
         ]. Genetic studies also provide some support for a causal association of HDL-C with CKD [
         <a href="#rid19">
          19,43,44
         </a>
         ].
        </p>
        <p>
         One of the possible explanations why the relationship between HDL-cholesterol and various outcomes is not straightforward is the fact that routine assays measure only one component of the HDL particles, namely HDL cholesterol. However, an HDL particle consists of more than 80 proteins and several hundred lipid species with various functions [
         <a href="#rid9">
          9,45
         </a>
         ]. Changes in functional properties of the HDL particle result in impaired cholesterol efflux capacity and impaired reverse cholesterol transport from peripheral cells such as cholesterol-laden macrophages to the liver, resulting in an increased risk for atherosclerotic cardiovascular diseases [
         <a href="#rid46">
          46
         </a>
         ]. There are, however, few studies on changes in reverse cholesterol transport in patients with CKD [
         <a href="#rid8">
          8,47
         </a>
         ].
        </p>
        <p>
         The composition of HDL particles and their atheroprotective properties in patients with CKD may be different from those in patients without CKD. Our understanding of the roles of many of these HDL components in the pathogenesis of kidney and cardiovascular disease is still rather rudimentary [
         <a href="#rid8">
          8
         </a>
         ]. As an example, there is downregulation of lecithin-cholesterol acyltransferase, which results in reduced esterification of cholesterol and therefore reduced reverse cholesterol transport [
         <a href="#rid48">
          48
         </a>
         ]. Other components of the HDL particle with major changes in patients with CKD are serum amyloid A, asymmetric dimethylarginine (ADMA) and symmetric dimethylarginine (SDMA), advanced oxidation protein products (AOPP), apolipoprotein A-IV, and various microRNAs. In the 4D trial that included patients on hemodialysis with diabetes mellitus, higher serum amyloid A in the HDL particle was predictive of a higher risk of a cardiac event rate [
         <a href="#rid49">
          49
         </a>
         ]. In the same study, low serum apolipoprotein A-IV concentrations were associated with an increased risk for all-cause mortality and sudden cardiac arrest [
         <a href="#rid50">
          50
         </a>
         ]. Along the same line, higher serum apolipoprotein A-IV was found to be an independent risk marker for reduced all-cause mortality, cardiovascular events, and heart failure in a cohort of more than 5000 patients with moderate CKD in the German Chronic Kidney Disease study [
         <a href="#rid12">
          12
         </a>
         ]. These and several other studies support the concept of dysfunctional HDL in the pathogenesis of atherosclerotic cardiovascular disease in CKD [
         <a href="#rid51">
          51,52
         </a>
         ], although not all studies reached similar conclusions [
         <a href="#rid53">
          53
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H2927673417">
         <span class="h2">
          Lipoprotein(a)
         </span>
         <span class="headingEndMark">
          —
         </span>
         Plasma Lp(a) concentrations increase with decreasing GFR, but they are highest in patients with nephrotic syndrome and in patients on peritoneal dialysis [
         <a href="#rid11">
          11,54-56
         </a>
         ].
        </p>
        <p>
         The role of the kidney in the metabolism of Lp(a) is not fully understood. Lower Lp(a) concentrations in the renal vein compared with the renal artery [
         <a href="#rid57">
          57
         </a>
         ] and fragments of apolipoprotein(a), the major apolipoprotein of Lp(a), in urine [
         <a href="#rid58">
          58,59
         </a>
         ] suggest an important function of the kidney in its catabolism. Turnover studies using stable isotope technology revealed an impaired catabolism of Lp(a) in patients on hemodialysis [
         <a href="#rid54">
          54
         </a>
         ] but an increased production rate in patients with nephrotic syndrome [
         <a href="#rid60">
          60
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/7190.html" rel="external">
          "Chronic kidney disease and coronary heart disease", section on 'Chronic kidney disease as an independent risk factor for CHD'
         </a>
         .)
        </p>
        <p>
         Two Mendelian randomization studies found that genetically increased serum Lp(a) concentrations were associated with an increased risk for CKD, suggesting that elevated Lp(a) concentrations in CKD are not only a consequence of CKD but may also contribute to the development of CKD [
         <a href="#rid44">
          44,61
         </a>
         ].
        </p>
        <p>
         In people without CKD, high Lp(a) concentrations are associated with a higher risk for cardiovascular disease, a finding bolstered by genetic studies [
         <a href="#rid62">
          62-64
         </a>
         ]. Accordingly, various guideline and consensus statements recommend testing Lp(a) at least once in each adult person to characterize cardiovascular risks [
         <a href="#rid45">
          45,65,66
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/4566.html" rel="external">
          "Lipoprotein(a)", section on 'Disease associations'
         </a>
         .)
        </p>
        <p>
         Similar associations between higher Lp(a) concentrations, and also higher genetically determined Lp(a) concentrations, and cardiovascular disease risk have been described in patients with CKD [
         <a href="#rid67">
          67-74
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H1914506959">
         <span class="h1">
          SCREENING AND MONITORING
         </span>
         <span class="headingEndMark">
          —
         </span>
         We screen all patients with CKD with a serum or plasma lipid panel that includes total cholesterol, low-density lipoprotein cholesterol (LDL-C), high-density lipoprotein cholesterol (HDL-C), and triglycerides. This approach is similar to screening recommendations for the general population. (See
         <a class="medical medical_review" href="/z/d/html/4553.html" rel="external">
          "Screening for lipid disorders in adults"
         </a>
         .)
        </p>
        <p>
         The sample should be obtained after at least nine hours of fasting. This is consistent with the 2013 Kidney Disease: Improving Global Outcomes (KDIGO) guidelines [
         <a href="#rid75">
          75
         </a>
         ].
        </p>
        <p>
         Many guidelines and consensus statements recommend the measurement of lipoprotein (a) (Lp(a)) for cardiovascular risk stratification in the general population, and that measurement of Lp(a) should be performed at least once in each person's lifetime [
         <a href="#rid45">
          45,65,66,76
         </a>
         ]. We follow the same guidance in patients with CKD, and we repeat the Lp(a) measurement when the CKD stage worsens, if nephrotic syndrome develops, or if the patient is placed on peritoneal dialysis. However, if the initial Lp(a) concentration is below 10 mg/dL, repeated measurements can be omitted since expected increases are unlikely to result in a pronounced change of risk category. (See
         <a class="medical medical_review" href="/z/d/html/4566.html" rel="external">
          "Lipoprotein(a)"
         </a>
         .)
        </p>
        <p>
         Among most patients, regardless of whether or not they are treated with statins, we recheck lipids annually (with the exception of Lp(a)). Annual measurements allow assessment of adherence, optimal dosing of medications, and consideration of additional cholesterol-lowering drugs such as
         <a class="drug drug_general" data-topicid="8790" href="/z/d/drug information/8790.html" rel="external">
          ezetimibe
         </a>
         , as well as further diet or lifestyle changes. Among patients with markedly abnormal values who may require titration of medications, we check lipids more frequently (ie, every three to six months). Monitoring of and targeting serum lipid profiles are similar to those recommended for the general non-CKD population. (See
         <a class="medical medical_review" href="/z/d/html/4549.html" rel="external">
          "Low-density lipoprotein cholesterol-lowering therapy in the primary prevention of cardiovascular disease"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/112841.html" rel="external">
          "Management of low density lipoprotein cholesterol (LDL-C) in the secondary prevention of cardiovascular disease"
         </a>
         .)
        </p>
        <p>
         The KDIGO guidelines take a somewhat different approach and state that routine follow-up monitoring of lipids in patients taking medication is not necessary but may be useful for detection of nonadherence [
         <a href="#rid30">
          30
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H4">
         <span class="h1">
          TREATMENT
         </span>
        </p>
        <p class="headingAnchor" id="H1455442837">
         <span class="h2">
          Management of LDL-C to reduce cardiovascular risk
         </span>
         <span class="headingEndMark">
          —
         </span>
         In general, management of low-density lipoprotein cholesterol (LDL-C) to reduce cardiovascular risk is similar in patients with nondialysis CKD and in patients without CKD [
         <a href="#rid77">
          77
         </a>
         ]. Our approach depends in part upon whether the patient already has established atherosclerotic cardiovascular disease (secondary prevention) or does not already have established atherosclerotic cardiovascular disease (primary prevention)  (
         <a class="graphic graphic_table graphicRef118900" href="/z/d/graphic/118900.html" rel="external">
          table 1
         </a>
         ). (See
         <a class="local">
          'Secondary prevention: Patients with CKD and established atherosclerotic cardiovascular disease'
         </a>
         below and
         <a class="local">
          'Primary prevention: Patients with CKD without established atherosclerotic cardiovascular disease'
         </a>
         below.)
        </p>
        <p>
         The use of lipid-lowering therapy in patients treated with dialysis, issues related to muscle toxicity, the general safety of statins in patients with CKD, and the effects of statins on cardiovascular and noncardiovascular outcomes are discussed separately. (See
         <a class="medical medical_review" href="/z/d/html/1962.html" rel="external">
          "Secondary prevention of cardiovascular disease in end-stage kidney disease (dialysis)", section on 'Lipid modification'
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/6833.html" rel="external">
          "Statin muscle-related adverse events"
         </a>
         .)
        </p>
        <p>
         The use of lipid-lowering therapy for transplant recipients is discussed elsewhere. (See
         <a class="medical medical_review" href="/z/d/html/7303.html" rel="external">
          "Lipid abnormalities after kidney transplantation", section on 'Treatment'
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H1417983115">
         <span class="h3">
          Secondary prevention: Patients with CKD and established atherosclerotic cardiovascular disease
         </span>
         <span class="headingEndMark">
          —
         </span>
         Patients with nondialysis CKD who have established atherosclerotic cardiovascular disease (prior history of coronary, cerebrovascular, peripheral arterial disease, or aortic aneurysm) should receive maximally tolerated statin therapy, similar to patients with established atherosclerotic cardiovascular disease who do not have CKD  (
         <a class="graphic graphic_table graphicRef118900" href="/z/d/graphic/118900.html" rel="external">
          table 1
         </a>
         ). In various trials of patients with established cardiovascular disease, the subgroups of patients with CKD derived similar relative benefits from statins on major outcomes as the subgroups without CKD [
         <a href="#rid78">
          78
         </a>
         ].
        </p>
        <p>
         The treatment of such patients, including goal LDL-C and monitoring, is presented separately. (See
         <a class="medical medical_review" href="/z/d/html/112841.html" rel="external">
          "Management of low density lipoprotein cholesterol (LDL-C) in the secondary prevention of cardiovascular disease", section on 'Our approach'
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/112841.html" rel="external">
          "Management of low density lipoprotein cholesterol (LDL-C) in the secondary prevention of cardiovascular disease"
         </a>
         .)
        </p>
        <p>
         Typically,
         <a class="drug drug_general" data-topicid="8949" href="/z/d/drug information/8949.html" rel="external">
          atorvastatin
         </a>
         is used in patients with CKD because renal dosing is not required, although other statins have been examined and shown to be beneficial in CKD populations as well [
         <a href="#rid75">
          75
         </a>
         ].
         <a class="drug drug_general" data-topicid="8790" href="/z/d/drug information/8790.html" rel="external">
          Ezetimibe
         </a>
         can be added to a statin if necessary to achieve the LDL-C target in patients with CKD. A PCSK9 inhibitor can also be added to a statin with or without ezetimibe, but it requires parenteral injection. (See
         <a class="medical medical_review" href="/z/d/html/4564.html" rel="external">
          "Statins: Actions, side effects, and administration", section on 'Chronic kidney disease'
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H2093808626">
         <span class="h3">
          Primary prevention: Patients with CKD without established atherosclerotic cardiovascular disease
         </span>
        </p>
        <p class="headingAnchor" id="H2405551765">
         <span class="h4">
          Our approach
         </span>
         <span class="headingEndMark">
          —
         </span>
         We recommend statin therapy for primary prevention (ie, in the absence of established atherosclerotic cardiovascular disease) in most patients with nondialysis CKD, although the practice differs somewhat among the UpToDate authors and editors  (
         <a class="graphic graphic_table graphicRef118900" href="/z/d/graphic/118900.html" rel="external">
          table 1
         </a>
         ):
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Since CKD per se is a cardiovascular risk factor, the authors of this topic and one of the section editors recommend statin therapy in
         <strong>
          all
         </strong>
         patients with an estimated glomerular filtration rate (eGFR) &lt;60 mL/min/1.73 m
         <sup>
          2
         </sup>
         , regardless of other cardiovascular risk factors or calculated cardiovascular risk score.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         These experts further suggest statin therapy for patients with CKD and eGFR ≥60 mL/min/1.73 m
         <sup>
          2
         </sup>
         if they are 50 years of age or older or have other cardiovascular risk factors (eg, diabetes, hypertension, smoking, low levels of high-density lipoprotein cholesterol [HDL-C], high levels of lipoprotein(a) [Lp(a)]).
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Other UpToDate contributors recommend statins for primary prevention in patients with nondialysis CKD if the predicted 10-year absolute risk of having a major cardiovascular event is 7.5 to 10 percent or greater but not if the predicted 10-year risk is less than 5 percent. Patients with a predicted 10-year risk of 5 to 7.5 percent are frequently offered treatment. This approach is similar to the management of LDL-C for primary prevention in patients without CKD.
        </p>
        <p>
        </p>
        <p>
         In general, we prescribe moderate-intensity statin therapy for
         <strong>
          primary
         </strong>
         prevention of cardiovascular disease (including in patients with CKD). The authors target a serum LDL-C concentration of &lt;70 mg/dL although other experts target a concentration &lt;100 mg/dL (see
         <a class="medical medical_review" href="/z/d/html/4549.html" rel="external">
          "Low-density lipoprotein cholesterol-lowering therapy in the primary prevention of cardiovascular disease"
         </a>
         ). The exception to moderate-intensity (rather than high-intensity) statin therapy is patients with suspected heterozygous or homozygous familial hypercholesterolemia (who typically have an LCL-C ≥190 mg/dL [4.9 mmol/L]). The evaluation and treatment of such patients are discussed elsewhere.
        </p>
        <p>
         Moderate-intensity statin doses that have shown benefit in patients with CKD include
         <a class="drug drug_general" data-topicid="8949" href="/z/d/drug information/8949.html" rel="external">
          atorvastatin
         </a>
         20 mg daily,
         <a class="drug drug_general" data-topicid="8473" href="/z/d/drug information/8473.html" rel="external">
          fluvastatin
         </a>
         80 mg daily,
         <a class="drug drug_general" data-topicid="9804" href="/z/d/drug information/9804.html" rel="external">
          pravastatin
         </a>
         40 mg daily,
         <a class="drug drug_general" data-topicid="10282" href="/z/d/drug information/10282.html" rel="external">
          rosuvastatin
         </a>
         10 mg daily, and
         <a class="drug drug_general" data-topicid="9923" href="/z/d/drug information/9923.html" rel="external">
          simvastatin
         </a>
         20 to 40 mg daily  (
         <a class="graphic graphic_table graphicRef93367" href="/z/d/graphic/93367.html" rel="external">
          table 2
         </a>
         ). Atorvastatin is frequently chosen for patients with CKD because it is metabolized by the liver and does not require renal dose adjustments. In addition, atorvastatin may have beneficial effects on proteinuria and preservation of kidney function [
         <a href="#rid75">
          75,79
         </a>
         ].
        </p>
        <p>
         As noted above, we monitor lipids annually and encourage treatment adherence as necessary based upon total cholesterol and LDL-C levels. (See
         <a class="local">
          'Screening and monitoring'
         </a>
         above.)
        </p>
        <p>
         Baseline transaminases should be checked among patients with CKD who are initiating statins, but subsequent monitoring of transaminases is probably not necessary, due to the low incidence of abnormalities among patients with normal baseline transaminases [
         <a href="#rid75">
          75
         </a>
         ]. We do not routinely monitor creatine kinase (CK) levels in the absence of symptoms of myopathy (see
         <a class="medical medical_review" href="/z/d/html/6833.html" rel="external">
          "Statin muscle-related adverse events"
         </a>
         ). An exception is in patients on statins in addition to other medications that also increase the risk of rhabdomyolysis (eg, fibric acid derivatives, calcineurin inhibitors).
        </p>
        <p>
         Adherent patients who do not respond to statin therapy by decreasing plasma LDL-C concentrations may have a high plasma Lp(a) concentration, since Lp(a) consists of a certain, albeit variable, amount of cholesterol, which is also measured as part of the plasma total cholesterol or LDL-C fraction [
         <a href="#rid80">
          80
         </a>
         ]. If a patient has an Lp(a) concentration of 200 mg/dL, roughly 40 to 60 mg/dL of the measured LDL-C would be derived from the Lp(a). Since Lp(a) levels are not influenced by statins [
         <a href="#rid81">
          81
         </a>
         ], the truly statin-accessible cholesterol (ie, Lp(a)-corrected LDL-C) is actually lower.
        </p>
        <p class="headingAnchor" id="H2734724208">
         <span class="h4">
          Rationale for our approach
         </span>
         <span class="headingEndMark">
          —
         </span>
         The best data supporting the use of statins for primary prevention of cardiovascular events in patients with nondialysis CKD come from the Study of Heart and Renal Protection (SHARP) trial and from meta-analyses of statin trials that included subgroups of patients with CKD. These data demonstrate a reduction in cardiovascular risk with statin therapy in patients with nondialysis CKD.
        </p>
        <p>
         The SHARP trial randomly assigned 9270 patients with CKD (including 6247 patients not on dialysis) who had a serum creatinine of at least 1.7 mg/dL (150 microm/L) for males, or 1.5 mg/dL (130 microm/L) for females, to placebo or to the combination of
         <a class="drug drug_general" data-topicid="9923" href="/z/d/drug information/9923.html" rel="external">
          simvastatin
         </a>
         20 mg daily plus
         <a class="drug drug_general" data-topicid="8790" href="/z/d/drug information/8790.html" rel="external">
          ezetimibe
         </a>
         (an inhibitor of intestinal cholesterol absorption) 10 mg daily [
         <a href="#rid82">
          82
         </a>
         ]. Nearly all patients had an eGFR &lt;60 mL/min/1.73 m
         <sup>
          2
         </sup>
         ; patients were not enrolled if they had a prior history of coronary heart disease (CHD). In the entire cohort and in the subgroup who were not treated with maintenance dialysis, simvastatin/ezetimibe lowered the incidence of the primary composite outcome of coronary death, myocardial infarction, ischemic stroke, or any revascularization procedure (11.3 versus 13.4 percent in the entire cohort and 9.5 versus 11.9 percent in the CKD subgroup) after 4.9 years of follow-up. Discontinuation of the study medication due to myalgia was significantly more common with simvastatin/ezetimibe therapy compared with placebo (1.1 versus 0.6 percent), but the rates of other adverse effects were similar between treatment groups. Despite the benefit on the combined endpoint, there was no difference between groups on all-cause mortality.
        </p>
        <p>
         These results are supported by meta-analyses of CKD subgroups from large statin trials for cardiovascular prevention [
         <a href="#rid78">
          78,83-85
         </a>
         ]; some of these meta-analyses also included the SHARP trial. Each of these studies found that statin therapy reduced the rates of cardiovascular events, cardiovascular mortality, and all-cause mortality. Most analyses reported outcomes among the combined group of patients on dialysis, kidney transplant recipients, as well as patients with nondialysis CKD; however, post-hoc subgroup analyses suggest that the beneficial effects are limited to patients not receiving dialysis [
         <a href="#rid83">
          83,84
         </a>
         ]. In one meta-analysis, among patients with CKD not receiving dialysis, statins were associated with a relative reduction in all-cause mortality (11 studies or subgroups; relative risk [RR] 0.81, 95% CI 0.74-0.88), cardiovascular mortality (8 studies or subgroups; RR 0.78 95% CI 0.68-0.89), and cardiovascular events (14 studies or subgroups; RR 0.76, 95% CI 0.73-0.80) [
         <a href="#rid78">
          78
         </a>
         ].
        </p>
        <p>
         The rationale to prescribe statins for all patients with nondialysis CKD with an eGFR &lt;60 mL/min/1.73 m
         <sup>
          2
         </sup>
         , and in many patients with CKD with higher eGFR values, is based upon the fact that even mild-to-moderate CKD (including albuminuria with a normal eGFR) is associated with an increased relative risk for cardiovascular disease [
         <a href="#rid86">
          86,87
         </a>
         ] and upon the data showing that cardiovascular risks can be reduced by statin treatment. (See
         <a class="medical medical_review" href="/z/d/html/7190.html" rel="external">
          "Chronic kidney disease and coronary heart disease"
         </a>
         .)
        </p>
        <p>
         The rationale to use predicted 10-year
         <strong>
          absolute
         </strong>
         cardiovascular risk to guide statin therapy is based upon the notion that, in general, therapeutic decisions are made based upon the absolute benefits and harms of a particular treatment and not the
         <strong>
          relative
         </strong>
         benefits and harms. This approach to deciding about statin therapy for primary prevention is discussed in detail elsewhere. (See
         <a class="medical medical_review" href="/z/d/html/4549.html" rel="external">
          "Low-density lipoprotein cholesterol-lowering therapy in the primary prevention of cardiovascular disease", section on 'Rationale for our approach and treatment goals'
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H569084032">
         <span class="h2">
          Management of other lipid disorders
         </span>
        </p>
        <p class="headingAnchor" id="H3827608481">
         <span class="h3">
          Lipid disorders in nephrotic syndrome
         </span>
         <span class="headingEndMark">
          —
         </span>
         Recommendations for hyperlipidemic patients with nephrotic syndrome and eGFR ≥60 mL/min/1.73 m
         <sup>
          2
         </sup>
         are discussed elsewhere.
        </p>
        <p class="headingAnchor" id="H587196842">
         <span class="h3">
          Hypertriglyceridemia
         </span>
         <span class="headingEndMark">
          —
         </span>
         The nonpharmacologic management of hypertriglyceridemia among patients with CKD (eg, dietary modification) is similar to that in the general population. Therapeutic lifestyle changes include dietary modification, weight reduction if overweight, increased physical activity, and reduced alcohol intake [
         <a href="#rid75">
          75,88
         </a>
         ]. Dietary modifications could be a low-fat diet (less than 15 percent of total calories), reduction of monosaccharides and disaccharides, reduction of dietary carbohydrates, and use of fish oils. Cautions should be taken in instituting dietary restriction in order to avoid malnutrition. (See
         <a class="medical medical_review" href="/z/d/html/4570.html" rel="external">
          "Hypertriglyceridemia in adults: Management", section on 'General measures'
         </a>
         .)
        </p>
        <p>
         We typically do
         <strong>
          not
         </strong>
         use fibrates, as they are more likely to produce side effects, particularly when given concurrently with statins [
         <a href="#rid75">
          75,88
         </a>
         ]. However, rare patients with CKD who have serum total triglycerides &gt;10 mmol/L (886 mg/dL) despite nonpharmacologic interventions may require specific pharmacologic treatment of triglycerides in order to prevent pancreatitis and possibly reduce cardiovascular risk. For these patients, fibrates are most effective in lowering serum triglyceride levels [
         <a href="#rid89">
          89
         </a>
         ]. Such patients should only be treated by clinicians with expertise in lipid disorders, and the dose needs to be adjusted for decreased kidney function. (See
         <a class="medical medical_review" href="/z/d/html/4570.html" rel="external">
          "Hypertriglyceridemia in adults: Management"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/6833.html" rel="external">
          "Statin muscle-related adverse events", section on 'Concurrent drug therapy'
         </a>
         .)
        </p>
        <p>
         <a class="drug drug_general" data-topicid="9695" href="/z/d/drug information/9695.html" rel="external">
          Niacin
         </a>
         also lowers serum triglyceride levels and increases serum HDL-C levels, although we seldom prescribe it in patients with CKD. The addition of niacin to statin did not reduce cardiovascular events in a trial of patients with CKD [
         <a href="#rid90">
          90
         </a>
         ]. Niacin also has side effects such as flushing and gastrointestinal distress. In addition, niacin is no longer available in many countries.
        </p>
        <p>
         The Veterans Affairs High-Density Lipoprotein Intervention Trial (VA-HIT) evaluated the effect of
         <a class="drug drug_general" data-topicid="8488" href="/z/d/drug information/8488.html" rel="external">
          gemfibrozil
         </a>
         in patients with established CHD and an HDL-C &lt;40 mg/dL (1.03 mmol/L). Within this cohort of 2531 people, there were 1044 males with impaired creatinine clearance, including 638 and 406 patients with creatinine clearances of 60 to 75 and 30 to 59.9 mL/min, respectively [
         <a href="#rid91">
          91
         </a>
         ]. Among these patients with impaired creatinine clearance, gemfibrozil therapy lowered the risk of the primary endpoint of coronary death and nonfatal myocardial infarction (18.2 versus 24.3 percent, hazard ratio [HR] 0.73, 95% CI 0.56-0.96). However, gemfibrozil therapy had no effect on total mortality (HR 1.03) and caused a significant decline in kidney function; 5.9 and 2.8 percent of gemfibrozil and placebo-treated patients, respectively, experienced a sustained increase in creatinine values that remained 0.5 mg/dL higher than baseline for the remainder of follow-up (p = 0.02).
        </p>
        <p class="headingAnchor" id="H1854766841">
         <span class="h3">
          Lipoprotein(a)
         </span>
         <span class="headingEndMark">
          —
         </span>
         There are no drugs that produce an isolated lowering of plasma Lp(a). However, post-hoc analyses from the PCSK9 trials FOURIER and ODYSSEY [
         <a href="#rid92">
          92
         </a>
         ] found that these agents reduce Lp(a) by 25 to 30 percent, which may contribute to the beneficial effects on the cardiovascular outcomes. However, the relative Lp(a)-lowering effect was only 15 to 20 percent in cases of high pretreatment Lp(a) values.
        </p>
        <p>
         Other treatments that can reduce Lp(a) include novel antisense oligonucleotides against apolipoprotein(a), the main protein of the Lp(a) particle, and lipoprotein apheresis. In preclinical studies, these antisense oligonucleotides lowered Lp(a) concentrations up to 90 percent [
         <a href="#rid93">
          93-96
         </a>
         ]. Whether this intervention also decreases cardiovascular events is unknown. In some countries, lipoprotein apheresis is used to treat patients with high Lp(a) concentrations and progressive cardiovascular disease despite optimal lipid-lowering medication. This intervention results in a dramatic lowering of cardiovascular events [
         <a href="#rid97">
          97
         </a>
         ], although sham apheresis was not performed as a control due to ethical concerns.
        </p>
        <p class="headingAnchor" id="H2460369168">
         <span class="h1">
          SOCIETY GUIDELINE LINKS
         </span>
         <span class="headingEndMark">
          —
         </span>
         Links to society and government-sponsored guidelines from selected countries and regions around the world are provided separately. (See
         <a class="medical medical_society_guidelines" href="/z/d/html/110749.html" rel="external">
          "Society guideline links: Chronic kidney disease in adults"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H7">
         <span class="h1">
          SUMMARY AND RECOMMENDATIONS
         </span>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Lipid abnormalities are common in patients with all stages of chronic kidney disease (CKD). Mild-to-moderate hypertriglyceridemia is the primary lipid abnormality among patients with CKD, although abnormalities in low-density lipoprotein cholesterol (LDL-C) and lipoprotein(a) (Lp(a)) also occur. (See
         <a class="local">
          'Introduction'
         </a>
         above and
         <a class="local">
          'Common lipid abnormalities'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         We screen all patients with CKD with a plasma lipid panel that includes total cholesterol, LDL-C, high-density lipoprotein cholesterol (HDL-C), and triglyceride concentrations. We obtain at least one measure of plasma Lp(a) concentration for cardiovascular risk stratification. We recheck lipids annually, with the exception of Lp(a). (See
         <a class="local">
          'Screening and monitoring'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         In general, management of LDL-C to reduce cardiovascular risk is similar in patients with nondialysis CKD and in patients without CKD. Our approach depends in part upon whether the patient already has established atherosclerotic cardiovascular disease (secondary prevention) or does not already have established atherosclerotic cardiovascular disease (primary prevention)  (
         <a class="graphic graphic_table graphicRef118900" href="/z/d/graphic/118900.html" rel="external">
          table 1
         </a>
         ) (see
         <a class="local">
          'Management of LDL-C to reduce cardiovascular risk'
         </a>
         above):
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Secondary prevention – Patients with nondialysis CKD who have established atherosclerotic cardiovascular disease (prior history of coronary, cerebrovascular, or peripheral arterial disease) should receive maximally tolerated statin therapy, similar to patients with established atherosclerotic cardiovascular disease who do not have CKD. Typically,
         <a class="drug drug_general" data-topicid="8949" href="/z/d/drug information/8949.html" rel="external">
          atorvastatin
         </a>
         is used in patients with CKD because renal dosing is not required, although other statins have been examined and shown to be beneficial in CKD populations as well. (See
         <a class="local">
          'Secondary prevention: Patients with CKD and established atherosclerotic cardiovascular disease'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         Statin dosing, LDL-C goal, and monitoring of such patients are presented separately. (See
         <a class="medical medical_review" href="/z/d/html/112841.html" rel="external">
          "Management of low density lipoprotein cholesterol (LDL-C) in the secondary prevention of cardiovascular disease", section on 'Our approach'
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/4564.html" rel="external">
          "Statins: Actions, side effects, and administration", section on 'Chronic kidney disease'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Primary prevention – We recommend statin therapy for primary prevention (ie, in the absence of established atherosclerotic cardiovascular disease) in most patients with nondialysis CKD, although the practice differs slightly among the UpToDate authors and editors  (
         <a class="graphic graphic_table graphicRef118900" href="/z/d/graphic/118900.html" rel="external">
          table 1
         </a>
         ):
        </p>
        <p>
        </p>
        <p class="bulletIndent3">
         <span class="glyph">
          -
         </span>
         The authors of this topic and one of the editors recommend statin therapy in all patients with an estimated glomerular filtration rate (eGFR) &lt;60 mL/min/1.73 m
         <sup>
          2
         </sup>
         and suggest statin therapy for patients with CKD and eGFR ≥60 mL/min/1.73 m
         <sup>
          2
         </sup>
         if they are 50 years of age or older or have other cardiovascular risk factors (eg, diabetes, hypertension, smoking, low levels of HDL-C, high levels of Lp(a)).
        </p>
        <p>
        </p>
        <p class="bulletIndent3">
         <span class="glyph">
          -
         </span>
         Other UpToDate contributors recommend statins for primary prevention in patients with nondialysis CKD if the predicted 10-year absolute risk of having a major cardiovascular event is 7.5 to 10 percent or greater but not if the predicted 10-year risk is less than 5 percent. Patients with a predicted 10-year risk of 5 to 7.5 percent are frequently offered treatment. This approach is similar to the management of LDL-C for primary prevention in patients without CKD. (See
         <a class="medical medical_review" href="/z/d/html/4549.html" rel="external">
          "Low-density lipoprotein cholesterol-lowering therapy in the primary prevention of cardiovascular disease"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Recommendations for hyperlipidemic patients with nephrotic syndrome and eGFR ≥60 mL/min/1.73 m
         <sup>
          2
         </sup>
         are discussed elsewhere.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         The nonpharmacologic management of hypertriglyceridemia among patients with CKD (eg, dietary modification, alcohol restriction, weight reduction, increase in physical activity) is similar to that in the general population. We typically do
         <strong>
          not
         </strong>
         use fibrates, as they are more likely to produce side effects in CKD, particularly when given concurrently with statins. However, rare patients with CKD who have serum total triglycerides &gt;10 mmol/L (886 mg/dL) despite nonpharmacologic interventions may require specific pharmacologic treatment of triglycerides in order to prevent pancreatitis and possibly reduce cardiovascular risk. (See
         <a class="medical medical_review" href="/z/d/html/4570.html" rel="external">
          "Hypertriglyceridemia in adults: Management"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/6833.html" rel="external">
          "Statin muscle-related adverse events", section on 'Concurrent drug therapy'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H2689853984">
         <span class="h1">
          ACKNOWLEDGMENT
         </span>
         <span class="headingEndMark">
          —
         </span>
         The UpToDate editorial staff acknowledges Gerald B Appel, MD, who contributed to earlier versions of this topic review.
        </p>
       </div>
       <div class="headingAnchor" id="references">
        <ol id="reference">
         <li>
          <a class="nounderline abstract_t">
           Wheeler DC, Bernard DB. Lipid abnormalities in the nephrotic syndrome: causes, consequences, and treatment. Am J Kidney Dis 1994; 23:331.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Appel G. Lipid abnormalities in renal disease. Kidney Int 1991; 39:169.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Sentí M, Romero R, Pedro-Botet J, et al. Lipoprotein abnormalities in hyperlipidemic and normolipidemic men on hemodialysis with chronic renal failure. Kidney Int 1992; 41:1394.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Attman PO, Samuelsson O, Alaupovic P. Lipoprotein metabolism and renal failure. Am J Kidney Dis 1993; 21:573.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Sechi LA, Zingaro L, De Carli S, et al. Increased serum lipoprotein(a) levels in patients with early renal failure. Ann Intern Med 1998; 129:457.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Afzali B, Haydar AA, Vinen K, Goldsmith DJ. From Finland to fatland: beneficial effects of statins for patients with chronic kidney disease. J Am Soc Nephrol 2004; 15:2161.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Kwan BC, Kronenberg F, Beddhu S, Cheung AK. Lipoprotein metabolism and lipid management in chronic kidney disease. J Am Soc Nephrol 2007; 18:1246.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Kronenberg F. HDL in CKD-The Devil Is in the Detail. J Am Soc Nephrol 2018; 29:1356.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Speer T, Ridker PM, von Eckardstein A, et al. Lipoproteins in chronic kidney disease: from bench to bedside. Eur Heart J 2021; 42:2170.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Weiner DE, Sarnak MJ. Managing dyslipidemia in chronic kidney disease. J Gen Intern Med 2004; 19:1045.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Kronenberg F. Causes and consequences of lipoprotein(a) abnormalities in kidney disease. Clin Exp Nephrol 2014; 18:234.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Schwaiger JP, Kollerits B, Steinbrenner I, et al. Apolipoprotein A-IV concentrations and clinical outcomes in a large chronic kidney disease cohort: Results from the GCKD study. J Intern Med 2022; 291:622.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Li P, Yang M, Hang D, et al. Risk Assessment for Longitudinal Trajectories of Modifiable Lifestyle Factors on Chronic Kidney Disease Burden in China: A Population-based Study. J Epidemiol 2022; 32:449.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Nakano T, Tanaka S, Tsuruya K, Kitazono T. Relationship between serum lipid concentrations and impaired renal function in patients with chronic kidney disease: the Fukuoka Kidney Disease Registry Study. Clin Exp Nephrol 2021; 25:385.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Lv S, Zhang H, Chen J, et al. The effect of triglycerides to high-density lipoprotein cholesterol ratio on the reduction of renal function: findings from China health and retirement longitudinal study (CHARLS). Lipids Health Dis 2021; 20:110.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Tsuruya K, Yoshida H, Nagata M, et al. Impact of the Triglycerides to High-Density Lipoprotein Cholesterol Ratio on the Incidence and Progression of CKD: A Longitudinal Study in a Large Japanese Population. Am J Kidney Dis 2015; 66:972.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Kim J, Bae YJ, Shin SJ, et al. The ratio of triglycerides to high-density lipoprotein cholesterol is associated with the risk of chronic kidney disease in Korean men. Lipids 2021; 56:475.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Soohoo M, Hashemi L, Hsiung JT, et al. Association of Serum Triglycerides and Renal Outcomes among 1.6 Million US Veterans. Nephron 2022; 146:457.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Lanktree MB, Thériault S, Walsh M, Paré G. HDL Cholesterol, LDL Cholesterol, and Triglycerides as Risk Factors for CKD: A Mendelian Randomization Study. Am J Kidney Dis 2018; 71:166.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Soohoo M, Hashemi L, Hsiung JT, et al. Risk of Atherosclerotic Cardiovascular Disease and Nonatherosclerotic Cardiovascular Disease Hospitalizations for Triglycerides Across Chronic Kidney Disease Stages Among 2.9 Million US Veterans. J Am Heart Assoc 2021; 10:e022988.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Lamprea-Montealegre JA, Staplin N, Herrington WG, et al. Apolipoprotein B, Triglyceride-Rich Lipoproteins, and Risk of Cardiovascular Events in Persons with CKD. Clin J Am Soc Nephrol 2020; 15:47.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Kim Y, Lee S, Lee Y, et al. Predictive value of triglyceride/high-density lipoprotein cholesterol for major clinical outcomes in advanced chronic kidney disease: a nationwide population-based study. Clin Kidney J 2021; 14:1961.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Soohoo M, Moradi H, Obi Y, et al. Serum triglycerides and mortality risk across stages of chronic kidney disease in 2 million U.S. veterans. J Clin Lipidol 2019; 13:744.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Chawla V, Greene T, Beck GJ, et al. Hyperlipidemia and long-term outcomes in nondiabetic chronic kidney disease. Clin J Am Soc Nephrol 2010; 5:1582.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Arnadottir M, Thysell H, Dallongeville J, et al. Evidence that reduced lipoprotein lipase activity is not a primary pathogenetic factor for hypertriglyceridemia in renal failure. Kidney Int 1995; 48:779.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Wilson DE, Chan IF, Cheung AK, et al. Retinyl ester retention in chronic renal failure. Further evidence for a defect in chylomicron remnant metabolism. Atherosclerosis 1985; 57:189.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Lacour B, Roullet JB, Liagre AM, et al. Serum lipoprotein disturbances in primary and secondary hyperparathyroidism and effects of parathyroidectomy. Am J Kidney Dis 1986; 8:422.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Liang K, Oveisi F, Vaziri ND. Role of secondary hyperparathyroidism in the genesis of hypertriglyceridemia and VLDL receptor deficiency in chronic renal failure. Kidney Int 1998; 53:626.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Akmal M, Perkins S, Kasim SE, et al. Verapamil prevents chronic renal failure-induced abnormalities in lipid metabolism. Am J Kidney Dis 1993; 22:158.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Cheung AK, Parker CJ, Ren K, Iverius PH. Increased lipase inhibition in uremia: identification of pre-beta-HDL as a major inhibitor in normal and uremic plasma. Kidney Int 1996; 49:1360.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Tonelli M, Muntner P, Lloyd A, et al. Association between LDL-C and risk of myocardial infarction in CKD. J Am Soc Nephrol 2013; 24:979.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Kovesdy CP, Anderson JE, Kalantar-Zadeh K. Inverse association between lipid levels and mortality in men with chronic kidney disease who are not yet on dialysis: effects of case mix and the malnutrition-inflammation-cachexia syndrome. J Am Soc Nephrol 2007; 18:304.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Shlipak MG, Fried LF, Cushman M, et al. Cardiovascular mortality risk in chronic kidney disease: comparison of traditional and novel risk factors. JAMA 2005; 293:1737.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Liu Y, Coresh J, Eustace JA, et al. Association between cholesterol level and mortality in dialysis patients: role of inflammation and malnutrition. JAMA 2004; 291:451.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Peev V, Nayer A, Contreras G. Dyslipidemia, malnutrition, inflammation, cardiovascular disease and mortality in chronic kidney disease. Curr Opin Lipidol 2014; 25:54.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Seres DS, Strain GW, Hashim SA, et al. Improvement of plasma lipoprotein profiles during high-flux dialysis. J Am Soc Nephrol 1993; 3:1409.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Lo JC, Go AS, Chandra M, et al. GFR, body mass index, and low high-density lipoprotein concentration in adults with and without CKD. Am J Kidney Dis 2007; 50:552.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Madsen CM, Varbo A, Nordestgaard BG. Extreme high high-density lipoprotein cholesterol is paradoxically associated with high mortality in men and women: two prospective cohort studies. Eur Heart J 2017; 38:2478.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Madsen CM, Varbo A, Tybjærg-Hansen A, et al. U-shaped relationship of HDL and risk of infectious disease: two prospective population-based cohort studies. Eur Heart J 2018; 39:1181.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Moradi H, Streja E, Kashyap ML, et al. Elevated high-density lipoprotein cholesterol and cardiovascular mortality in maintenance hemodialysis patients. Nephrol Dial Transplant 2014; 29:1554.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Navaneethan SD, Schold JD, Walther CP, et al. High-density lipoprotein cholesterol and causes of death in chronic kidney disease. J Clin Lipidol 2018; 12:1061.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Bowe B, Xie Y, Xian H, et al. Low levels of high-density lipoprotein cholesterol increase the risk of incident kidney disease and its progression. Kidney Int 2016; 89:886.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Coassin S, Friedel S, Köttgen A, et al. Is High-Density Lipoprotein Cholesterol Causally Related to Kidney Function? Evidence From Genetic Epidemiological Studies. Arterioscler Thromb Vasc Biol 2016; 36:2252.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Zheng J, Zhang Y, Rasheed H, et al. Trans-ethnic Mendelian-randomization study reveals causal relationships between cardiometabolic factors and chronic kidney disease. Int J Epidemiol 2022; 50:1995.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Kronenberg F, Mora S, Stroes ESG. Consensus and guidelines on lipoprotein(a) - seeing the forest through the trees. Curr Opin Lipidol 2022; 33:342.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Rohatgi A, Khera A, Berry JD, et al. HDL cholesterol efflux capacity and incident cardiovascular events. N Engl J Med 2014; 371:2383.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Schachtl-Riess JF, Schönherr S, Lamina C, et al. KLKB1 and CLSTN2 are associated with HDL-mediated cholesterol efflux capacity in a genome-wide association study. Atherosclerosis 2023; 368:1.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Yamamoto S, Kon V. Mechanisms for increased cardiovascular disease in chronic kidney dysfunction. Curr Opin Nephrol Hypertens 2009; 18:181.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Kopecky C, Genser B, Drechsler C, et al. Quantification of HDL proteins, cardiac events, and mortality in patients with type 2 diabetes on hemodialysis. Clin J Am Soc Nephrol 2015; 10:224.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Kollerits B, Krane V, Drechsler C, et al. Apolipoprotein A-IV concentrations and clinical outcomes in haemodialysis patients with type 2 diabetes mellitus--a post hoc analysis of the 4D Study. J Intern Med 2012; 272:592.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Rosenson RS, Brewer HB Jr, Barter PJ, et al. HDL and atherosclerotic cardiovascular disease: genetic insights into complex biology. Nat Rev Cardiol 2018; 15:9.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Rosenson RS, Brewer HB Jr, Ansell BJ, et al. Dysfunctional HDL and atherosclerotic cardiovascular disease. Nat Rev Cardiol 2016; 13:48.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Untersteller K, Meissl S, Trieb M, et al. HDL functionality and cardiovascular outcome among nondialysis chronic kidney disease patients. J Lipid Res 2018; 59:1256.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Frischmann ME, Kronenberg F, Trenkwalder E, et al. In vivo turnover study demonstrates diminished clearance of lipoprotein(a) in hemodialysis patients. Kidney Int 2007; 71:1036.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Muntner P, Hamm LL, Kusek JW, et al. The prevalence of nontraditional risk factors for coronary heart disease in patients with chronic kidney disease. Ann Intern Med 2004; 140:9.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Kronenberg F, Kuen E, Ritz E, et al. Lipoprotein(a) serum concentrations and apolipoprotein(a) phenotypes in mild and moderate renal failure. J Am Soc Nephrol 2000; 11:105.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Kronenberg F, Trenkwalder E, Lingenhel A, et al. Renovascular arteriovenous differences in Lp[a] plasma concentrations suggest removal of Lp[a] from the renal circulation. J Lipid Res 1997; 38:1755.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Mooser V, Marcovina SM, White AL, Hobbs HH. Kringle-containing fragments of apolipoprotein(a) circulate in human plasma and are excreted into the urine. J Clin Invest 1996; 98:2414.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Kostner KM, Maurer G, Huber K, et al. Urinary excretion of apo(a) fragments. Role in apo(a) catabolism. Arterioscler Thromb Vasc Biol 1996; 16:905.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           De Sain-Van Der Velden MG, Reijngoud DJ, Kaysen GA, et al. Evidence for increased synthesis of lipoprotein(a) in the nephrotic syndrome. J Am Soc Nephrol 1998; 9:1474.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Satterfield BA, Dikilitas O, Safarova MS, et al. Associations of Genetically Predicted Lp(a) (Lipoprotein [a]) Levels With Cardiovascular Traits in Individuals of European and African Ancestry. Circ Genom Precis Med 2021; 14:e003354.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Nordestgaard BG, Langsted A. Lipoprotein (a) as a cause of cardiovascular disease: insights from epidemiology, genetics, and biology. J Lipid Res 2016; 57:1953.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Kronenberg F, Utermann G. Lipoprotein(a): resurrected by genetics. J Intern Med 2013; 273:6.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Catapano AL, Graham I, De Backer G, et al. 2016 ESC/EAS Guidelines for the Management of Dyslipidaemias. Eur Heart J 2016; 37:2999.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Pearson GJ, Thanassoulis G, Anderson TJ, et al. 2021 Canadian Cardiovascular Society Guidelines for the Management of Dyslipidemia for the Prevention of Cardiovascular Disease in Adults. Can J Cardiol 2021; 37:1129.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Kronenberg F, Mora S, Stroes ESG, et al. Lipoprotein(a) in atherosclerotic cardiovascular disease and aortic stenosis: a European Atherosclerosis Society consensus statement. Eur Heart J 2022; 43:3925.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Kronenberg F, Neyer U, Lhotta K, et al. The low molecular weight apo(a) phenotype is an independent predictor for coronary artery disease in hemodialysis patients: a prospective follow-up. J Am Soc Nephrol 1999; 10:1027.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Coassin S, Erhart G, Weissensteiner H, et al. A novel but frequent variant in LPA KIV-2 is associated with a pronounced Lp(a) and cardiovascular risk reduction. Eur Heart J 2017; 38:1823.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Bajaj A, Damrauer SM, Anderson AH, et al. Lipoprotein(a) and Risk of Myocardial Infarction and Death in Chronic Kidney Disease: Findings From the CRIC Study (Chronic Renal Insufficiency Cohort). Arterioscler Thromb Vasc Biol 2017; 37:1971.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Longenecker JC, Klag MJ, Marcovina SM, et al. High lipoprotein(a) levels and small apolipoprotein(a) size prospectively predict cardiovascular events in dialysis patients. J Am Soc Nephrol 2005; 16:1794.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Longenecker JC, Klag MJ, Marcovina SM, et al. Small apolipoprotein(a) size predicts mortality in end-stage renal disease: The CHOICE study. Circulation 2002; 106:2812.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Li Q, Chen Y, Yu L, et al. The relationship between lipoprotein(a) and cardiovascular events in acute coronary syndrome patients with and without chronic kidney disease. Atherosclerosis 2022; 349:204.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Xu N, Tang XF, Yao Y, et al. Association of Plasma Lipoprotein(a) With Long-Term Adverse Events in Patients With Chronic Kidney Disease Who Underwent Percutaneous Coronary Intervention. Am J Cardiol 2018; 122:2043.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Konishi H, Miyauchi K, Tsuboi S, et al. Plasma lipoprotein(a) predicts major cardiovascular events in patients with chronic kidney disease who undergo percutaneous coronary intervention. Int J Cardiol 2016; 205:50.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           KDIGO Clinical Practice Guideline for Lipid Management in Chronic Kidney Disease. Kidney Int Suppl 2013; 3:263.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Mach F, Baigent C, Catapano AL, et al. 2019 ESC/EAS Guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk. Eur Heart J 2020; 41:111.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Grundy SM, Stone NJ, Bailey AL, et al. 2018 AHA/ACC/AACVPR/AAPA/ABC/ACPM/ADA/AGS/APhA/ASPC/NLA/PCNA Guideline on the Management of Blood Cholesterol: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. J Am Coll Cardiol 2019; 73:e285.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Palmer SC, Craig JC, Navaneethan SD, et al. Benefits and harms of statin therapy for persons with chronic kidney disease: a systematic review and meta-analysis. Ann Intern Med 2012; 157:263.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           de Zeeuw D, Anzalone DA, Cain VA, et al. Renal effects of atorvastatin and rosuvastatin in patients with diabetes who have progressive renal disease (PLANET I): a randomised clinical trial. Lancet Diabetes Endocrinol 2015; 3:181.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Kronenberg F, Lingenhel A, Lhotta K, et al. Lipoprotein(a)- and low-density lipoprotein-derived cholesterol in nephrotic syndrome: Impact on lipid-lowering therapy? Kidney Int 2004; 66:348.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Khera AV, Everett BM, Caulfield MP, et al. Lipoprotein(a) concentrations, rosuvastatin therapy, and residual vascular risk: an analysis from the JUPITER Trial (Justification for the Use of Statins in Prevention: an Intervention Trial Evaluating Rosuvastatin). Circulation 2014; 129:635.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Baigent C, Landray MJ, Reith C, et al. The effects of lowering LDL cholesterol with simvastatin plus ezetimibe in patients with chronic kidney disease (Study of Heart and Renal Protection): a randomised placebo-controlled trial. Lancet 2011; 377:2181.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Navaneethan SD, Pansini F, Perkovic V, et al. HMG CoA reductase inhibitors (statins) for people with chronic kidney disease not requiring dialysis. Cochrane Database Syst Rev 2009; :CD007784.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Upadhyay A, Earley A, Lamont JL, et al. Lipid-lowering therapy in persons with chronic kidney disease: a systematic review and meta-analysis. Ann Intern Med 2012; 157:251.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Hou W, Lv J, Perkovic V, et al. Effect of statin therapy on cardiovascular and renal outcomes in patients with chronic kidney disease: a systematic review and meta-analysis. Eur Heart J 2013; 34:1807.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Matsushita K, Coresh J, Sang Y, et al. Estimated glomerular filtration rate and albuminuria for prediction of cardiovascular outcomes: a collaborative meta-analysis of individual participant data. Lancet Diabetes Endocrinol 2015; 3:514.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Matsushita K, Ballew SH, Coresh J, et al. Measures of chronic kidney disease and risk of incident peripheral artery disease: a collaborative meta-analysis of individual participant data. Lancet Diabetes Endocrinol 2017; 5:718.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Sarnak MJ, Bloom R, Muntner P, et al. KDOQI US commentary on the 2013 KDIGO Clinical Practice Guideline for Lipid Management in CKD. Am J Kidney Dis 2015; 65:354.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Nishizawa Y, Shoji T, Nishitani H, et al. Hypertriglyceridemia and lowered apolipoprotein C-II/C-III ratio in uremia: effect of a fibric acid, clinofibrate. Kidney Int 1993; 44:1352.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Kalil RS, Wang JH, de Boer IH, et al. Effect of extended-release niacin on cardiovascular events and kidney function in chronic kidney disease: a post hoc analysis of the AIM-HIGH trial. Kidney Int 2015; 87:1250.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Tonelli M, Collins D, Robins S, et al. Gemfibrozil for secondary prevention of cardiovascular events in mild to moderate chronic renal insufficiency. Kidney Int 2004; 66:1123.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Kronenberg F. Therapeutic lowering of lipoprotein(a): How much is enough? Atherosclerosis 2019; 288:163.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Viney NJ, van Capelleveen JC, Geary RS, et al. Antisense oligonucleotides targeting apolipoprotein(a) in people with raised lipoprotein(a): two randomised, double-blind, placebo-controlled, dose-ranging trials. Lancet 2016; 388:2239.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Nissen SE, Wolski K, Balog C, et al. Single Ascending Dose Study of a Short Interfering RNA Targeting Lipoprotein(a) Production in Individuals With Elevated Plasma Lipoprotein(a) Levels. JAMA 2022; 327:1679.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           O'Donoghue ML, Rosenson RS, Gencer B, et al. Small Interfering RNA to Reduce Lipoprotein(a) in Cardiovascular Disease. N Engl J Med 2022; 387:1855.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Tsimikas S, Karwatowska-Prokopczuk E, Gouni-Berthold I, et al. Lipoprotein(a) Reduction in Persons with Cardiovascular Disease. N Engl J Med 2020; 382:244.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Roeseler E, Julius U, Heigl F, et al. Lipoprotein Apheresis for Lipoprotein(a)-Associated Cardiovascular Disease: Prospective 5 Years of Follow-Up and Apolipoprotein(a) Characterization. Arterioscler Thromb Vasc Biol 2016; 36:2019.
          </a>
         </li>
        </ol>
       </div>
       <div id="topicVersionRevision">
        Topic 7204 Version 38.0
       </div>
      </div>
      <div class="row">
       <div class="col-12">
        <h4 style="text-align: center;padding: 20px;color: cadetblue;">
         References
        </h4>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/8128933" id="rid0" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          1 : Lipid abnormalities in the nephrotic syndrome: causes, consequences, and treatment.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/2002630" id="rid1" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          2 : Lipid abnormalities in renal disease.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/1614054" id="rid2" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          3 : Lipoprotein abnormalities in hyperlipidemic and normolipidemic men on hemodialysis with chronic renal failure.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/8503411" id="rid3" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          4 : Lipoprotein metabolism and renal failure.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/9735083" id="rid4" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          5 : Increased serum lipoprotein(a) levels in patients with early renal failure.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15284301" id="rid5" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          6 : From Finland to fatland: beneficial effects of statins for patients with chronic kidney disease.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/17360943" id="rid6" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          7 : Lipoprotein metabolism and lipid management in chronic kidney disease.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/29472417" id="rid7" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          8 : HDL in CKD-The Devil Is in the Detail.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/33393990" id="rid8" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          9 : Lipoproteins in chronic kidney disease: from bench to bedside.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15482558" id="rid9" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          10 : Managing dyslipidemia in chronic kidney disease.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/24129557" id="rid10" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          11 : Causes and consequences of lipoprotein(a) abnormalities in kidney disease.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/34914850" id="rid11" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          12 : Apolipoprotein A-IV concentrations and clinical outcomes in a large chronic kidney disease cohort: Results from the GCKD study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/33814506" id="rid12" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          13 : Risk Assessment for Longitudinal Trajectories of Modifiable Lifestyle Factors on Chronic Kidney Disease Burden in China: A Population-based Study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/33398604" id="rid13" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          14 : Relationship between serum lipid concentrations and impaired renal function in patients with chronic kidney disease: the Fukuoka Kidney Disease Registry Study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/34544446" id="rid14" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          15 : The effect of triglycerides to high-density lipoprotein cholesterol ratio on the reduction of renal function: findings from China health and retirement longitudinal study (CHARLS).
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/26145254" id="rid15" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          16 : Impact of the Triglycerides to High-Density Lipoprotein Cholesterol Ratio on the Incidence and Progression of CKD: A Longitudinal Study in a Large Japanese Population.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/34089267" id="rid16" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          17 : The ratio of triglycerides to high-density lipoprotein cholesterol is associated with the risk of chronic kidney disease in Korean men.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/35354153" id="rid17" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          18 : Association of Serum Triglycerides and Renal Outcomes among 1.6 Million US Veterans.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/28754456" id="rid18" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          19 : HDL Cholesterol, LDL Cholesterol, and Triglycerides as Risk Factors for CKD: A Mendelian Randomization Study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/34729994" id="rid19" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          20 : Risk of Atherosclerotic Cardiovascular Disease and Nonatherosclerotic Cardiovascular Disease Hospitalizations for Triglycerides Across Chronic Kidney Disease Stages Among 2.9 Million US Veterans.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/31831577" id="rid20" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          21 : Apolipoprotein B, Triglyceride-Rich Lipoproteins, and Risk of Cardiovascular Events in Persons with CKD.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/34345420" id="rid21" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          22 : Predictive value of triglyceride/high-density lipoprotein cholesterol for major clinical outcomes in advanced chronic kidney disease: a nationwide population-based study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/31562050" id="rid22" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          23 : Serum triglycerides and mortality risk across stages of chronic kidney disease in 2 million U.S. veterans.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/20558558" id="rid23" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          24 : Hyperlipidemia and long-term outcomes in nondiabetic chronic kidney disease.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/7474664" id="rid24" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          25 : Evidence that reduced lipoprotein lipase activity is not a primary pathogenetic factor for hypertriglyceridemia in renal failure.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/4084353" id="rid25" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          26 : Retinyl ester retention in chronic renal failure. Further evidence for a defect in chylomicron remnant metabolism.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/3812471" id="rid26" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          27 : Serum lipoprotein disturbances in primary and secondary hyperparathyroidism and effects of parathyroidectomy.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/9507207" id="rid27" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          28 : Role of secondary hyperparathyroidism in the genesis of hypertriglyceridemia and VLDL receptor deficiency in chronic renal failure.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/8322779" id="rid28" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          29 : Verapamil prevents chronic renal failure-induced abnormalities in lipid metabolism.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/8731101" id="rid29" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          30 : Increased lipase inhibition in uremia: identification of pre-beta-HDL as a major inhibitor in normal and uremic plasma.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/23687359" id="rid30" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          31 : Association between LDL-C and risk of myocardial infarction in CKD.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/17167114" id="rid31" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          32 : Inverse association between lipid levels and mortality in men with chronic kidney disease who are not yet on dialysis: effects of case mix and the malnutrition-inflammation-cachexia syndrome.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15827312" id="rid32" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          33 : Cardiovascular mortality risk in chronic kidney disease: comparison of traditional and novel risk factors.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/14747502" id="rid33" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          34 : Association between cholesterol level and mortality in dialysis patients: role of inflammation and malnutrition.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/24345987" id="rid34" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          35 : Dyslipidemia, malnutrition, inflammation, cardiovascular disease and mortality in chronic kidney disease.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/8439653" id="rid35" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          36 : Improvement of plasma lipoprotein profiles during high-flux dialysis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/17900454" id="rid36" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          37 : GFR, body mass index, and low high-density lipoprotein concentration in adults with and without CKD.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/28419274" id="rid37" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          38 : Extreme high high-density lipoprotein cholesterol is paradoxically associated with high mortality in men and women: two prospective cohort studies.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/29228167" id="rid38" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          39 : U-shaped relationship of HDL and risk of infectious disease: two prospective population-based cohort studies.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/24574544" id="rid39" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          40 : Elevated high-density lipoprotein cholesterol and cardiovascular mortality in maintenance hemodialysis patients.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/29699917" id="rid40" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          41 : High-density lipoprotein cholesterol and causes of death in chronic kidney disease.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/26924057" id="rid41" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          42 : Low levels of high-density lipoprotein cholesterol increase the risk of incident kidney disease and its progression.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/27687604" id="rid42" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          43 : Is High-Density Lipoprotein Cholesterol Causally Related to Kidney Function? Evidence From Genetic Epidemiological Studies.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/34999880" id="rid43" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          44 : Trans-ethnic Mendelian-randomization study reveals causal relationships between cardiometabolic factors and chronic kidney disease.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/36251423" id="rid44" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          45 : Consensus and guidelines on lipoprotein(a) - seeing the forest through the trees.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/25404125" id="rid45" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          46 : HDL cholesterol efflux capacity and incident cardiovascular events.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/36812656" id="rid46" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          47 : KLKB1 and CLSTN2 are associated with HDL-mediated cholesterol efflux capacity in a genome-wide association study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/19374004" id="rid47" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          48 : Mechanisms for increased cardiovascular disease in chronic kidney dysfunction.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/25424990" id="rid48" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          49 : Quantification of HDL proteins, cardiac events, and mortality in patients with type 2 diabetes on hemodialysis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/22891946" id="rid49" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          50 : Apolipoprotein A-IV concentrations and clinical outcomes in haemodialysis patients with type 2 diabetes mellitus--a post hoc analysis of the 4D Study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/28795686" id="rid50" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          51 : HDL and atherosclerotic cardiovascular disease: genetic insights into complex biology.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/26323267" id="rid51" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          52 : Dysfunctional HDL and atherosclerotic cardiovascular disease.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/29789355" id="rid52" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          53 : HDL functionality and cardiovascular outcome among nondialysis chronic kidney disease patients.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/17299521" id="rid53" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          54 : In vivo turnover study demonstrates diminished clearance of lipoprotein(a) in hemodialysis patients.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/14706967" id="rid54" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          55 : The prevalence of nontraditional risk factors for coronary heart disease in patients with chronic kidney disease.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/10616846" id="rid55" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          56 : Lipoprotein(a) serum concentrations and apolipoprotein(a) phenotypes in mild and moderate renal failure.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/9323585" id="rid56" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          57 : Renovascular arteriovenous differences in Lp[a] plasma concentrations suggest removal of Lp[a]from the renal circulation.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/8941661" id="rid57" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          58 : Kringle-containing fragments of apolipoprotein(a) circulate in human plasma and are excreted into the urine.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/8696952" id="rid58" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          59 : Urinary excretion of apo(a) fragments. Role in apo(a) catabolism.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/9697670" id="rid59" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          60 : Evidence for increased synthesis of lipoprotein(a) in the nephrotic syndrome.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/34282949" id="rid60" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          61 : Associations of Genetically Predicted Lp(a) (Lipoprotein [a]) Levels With Cardiovascular Traits in Individuals of European and African Ancestry.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/27677946" id="rid61" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          62 : Lipoprotein (a) as a cause of cardiovascular disease: insights from epidemiology, genetics, and biology.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/22998429" id="rid62" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          63 : Lipoprotein(a): resurrected by genetics.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/27567407" id="rid63" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          64 : 2016 ESC/EAS Guidelines for the Management of Dyslipidaemias.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/33781847" id="rid64" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          65 : 2021 Canadian Cardiovascular Society Guidelines for the Management of Dyslipidemia for the Prevention of Cardiovascular Disease in Adults.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/36036785" id="rid65" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          66 : Lipoprotein(a) in atherosclerotic cardiovascular disease and aortic stenosis: a European Atherosclerosis Society consensus statement.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/10232689" id="rid66" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          67 : The low molecular weight apo(a) phenotype is an independent predictor for coronary artery disease in hemodialysis patients: a prospective follow-up.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/28444229" id="rid67" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          68 : A novel but frequent variant in LPA KIV-2 is associated with a pronounced Lp(a) and cardiovascular risk reduction.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/28838919" id="rid68" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          69 : Lipoprotein(a) and Risk of Myocardial Infarction and Death in Chronic Kidney Disease: Findings From the CRIC Study (Chronic Renal Insufficiency Cohort).
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15800123" id="rid69" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          70 : High lipoprotein(a) levels and small apolipoprotein(a) size prospectively predict cardiovascular events in dialysis patients.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/12451008" id="rid70" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          71 : Small apolipoprotein(a) size predicts mortality in end-stage renal disease: The CHOICE study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/35450749" id="rid71" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          72 : The relationship between lipoprotein(a) and cardiovascular events in acute coronary syndrome patients with and without chronic kidney disease.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/30477725" id="rid72" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          73 : Association of Plasma Lipoprotein(a) With Long-Term Adverse Events in Patients With Chronic Kidney Disease Who Underwent Percutaneous Coronary Intervention.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/26710333" id="rid73" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          74 : Plasma lipoprotein(a) predicts major cardiovascular events in patients with chronic kidney disease who undergo percutaneous coronary intervention.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/" id="rid74" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          75 : KDIGO Clinical Practice Guideline for Lipid Management in Chronic Kidney Disease
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/31504418" id="rid75" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          76 : 2019 ESC/EAS Guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/30423393" id="rid76" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          77 : 2018 AHA/ACC/AACVPR/AAPA/ABC/ACPM/ADA/AGS/APhA/ASPC/NLA/PCNA Guideline on the Management of Blood Cholesterol: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/22910937" id="rid77" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          78 : Benefits and harms of statin therapy for persons with chronic kidney disease: a systematic review and meta-analysis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/25660356" id="rid78" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          79 : Renal effects of atorvastatin and rosuvastatin in patients with diabetes who have progressive renal disease (PLANET I): a randomised clinical trial.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15200443" id="rid79" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          80 : Lipoprotein(a)- and low-density lipoprotein-derived cholesterol in nephrotic syndrome: Impact on lipid-lowering therapy?
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/24243886" id="rid80" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          81 : Lipoprotein(a) concentrations, rosuvastatin therapy, and residual vascular risk: an analysis from the JUPITER Trial (Justification for the Use of Statins in Prevention: an Intervention Trial Evaluating Rosuvastatin).
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/21663949" id="rid81" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          82 : The effects of lowering LDL cholesterol with simvastatin plus ezetimibe in patients with chronic kidney disease (Study of Heart and Renal Protection): a randomised placebo-controlled trial.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/19370693" id="rid82" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          83 : HMG CoA reductase inhibitors (statins) for people with chronic kidney disease not requiring dialysis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/22910936" id="rid83" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          84 : Lipid-lowering therapy in persons with chronic kidney disease: a systematic review and meta-analysis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/23470492" id="rid84" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          85 : Effect of statin therapy on cardiovascular and renal outcomes in patients with chronic kidney disease: a systematic review and meta-analysis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/26028594" id="rid85" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          86 : Estimated glomerular filtration rate and albuminuria for prediction of cardiovascular outcomes: a collaborative meta-analysis of individual participant data.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/28716631" id="rid86" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          87 : Measures of chronic kidney disease and risk of incident peripheral artery disease: a collaborative meta-analysis of individual participant data.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/25465166" id="rid87" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          88 : KDOQI US commentary on the 2013 KDIGO Clinical Practice Guideline for Lipid Management in CKD.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/8301936" id="rid88" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          89 : Hypertriglyceridemia and lowered apolipoprotein C-II/C-III ratio in uremia: effect of a fibric acid, clinofibrate.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/25651367" id="rid89" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          90 : Effect of extended-release niacin on cardiovascular events and kidney function in chronic kidney disease: a post hoc analysis of the AIM-HIGH trial.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15327407" id="rid90" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          91 : Gemfibrozil for secondary prevention of cardiovascular events in mild to moderate chronic renal insufficiency.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/31327477" id="rid91" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          92 : Therapeutic lowering of lipoprotein(a): How much is enough?
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/27665230" id="rid92" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          93 : Antisense oligonucleotides targeting apolipoprotein(a) in people with raised lipoprotein(a): two randomised, double-blind, placebo-controlled, dose-ranging trials.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/35368052" id="rid93" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          94 : Single Ascending Dose Study of a Short Interfering RNA Targeting Lipoprotein(a) Production in Individuals With Elevated Plasma Lipoprotein(a) Levels.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/36342163" id="rid94" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          95 : Small Interfering RNA to Reduce Lipoprotein(a) in Cardiovascular Disease.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/31893580" id="rid95" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          96 : Lipoprotein(a) Reduction in Persons with Cardiovascular Disease.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/27417585" id="rid96" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          97 : Lipoprotein Apheresis for Lipoprotein(a)-Associated Cardiovascular Disease: Prospective 5 Years of Follow-Up and Apolipoprotein(a) Characterization.
         </p>
        </a>
       </div>
      </div>
     </div>
    </div>
   </section>
  </section>
  <!-- End Main Menu Area -->
  <!-- Start Search Popup Area -->
  <!-- End Footer Area -->
  <!-- Back to top -->
  <a class="scrolltop" href="#top">
   <i class="icofont-hand-drawn-up">
   </i>
  </a>
  <!-- End Back to top -->
  <!-- jQuery Min JS -->
  <!-- Prpper JS -->
  <!-- Bootstrap Min JS -->
  <!-- Classy Nav Min Js -->
  <!-- Owl Carousel Min Js -->
  <!-- Magnific Popup JS -->
  <!-- CounterUp JS -->
  <!-- Waypoints JS -->
  <!-- Form Validator Min JS -->
  <!-- Contact Form Min JS -->
  <!-- Main JS -->
  <!-- Global site tag (gtag.js) - Google Analytics -->
 </body>
</html>
